Clinical Trials List
Protocol NumberGESRTCWA
NCT Number(ClinicalTrials.gov Identfier)NCT01796795
2013-11-29 - 2013-11-29
Phase II
Study ended4
A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.
-
Trial Applicant
A2 HEALTHCARE TAIWAN CORPORATION
-
Sponsor
G&E Herbal Biotechnology Co., LTD
-
Trial scale
Taiwan Multiple Center
-
Update
2025/08/20
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
- 林尚宏 Division of Dermatology
- Chih-Hung Lee Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
- SHIH-TSUNG CHENG Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Study ended
Principal Investigator
Co-Principal Investigator
- Chao-Chun Yang Division of Dermatology
- 林子凱 Division of Dermatology
- 許漢銘 Division of Dermatology
- Chao-Kai Hsu Division of Dermatology
- 趙曉秋 Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Study ended
Condition/Disease
Common Warts / Verruca Vulgaris (CWs)
Objectives
This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.
Test Drug
SR-T100
Active Ingredient
Solanum incanum extract (solamargine alkaloid )
Dosage Form
Gel for External Use
Dosage
1.0% and 2.3%
Endpoints
Primary Outcome Measures :
Total clearance rate of treated CW [ Time Frame: 16 weeks ]
Secondary Outcome Measures :
Proportion of patient with at least 75% reduction in CW lesion counts [ Time Frame: 16 weeks ]
Proportion of patient with at least 50% reduction in lesion size (volume) [ Time Frame: 16 weeks ]
Mean of percent reduction in CW lesion counts from individual patient by visit [ Time Frame: 16 weeks ]
Mean of percent reduction in CW lesion size from individual patient by visit [ Time Frame: 16 weeks ]
CW recurrence rate [ Time Frame: 28 weeks ]
Time to complete clearance [ Time Frame: 16 weeks ]
Percent reduction for pooled lesion counts by visit [ Time Frame: 16 weeks ]
Safety: evaluate the changes occurring from baseline (Randomization visit) to EOT visit. [ Time Frame: 28 weeks ]
including PE, vital sign, lab. test, local skin reaction, and adverse event, etc.
Total clearance rate of treated CW [ Time Frame: 16 weeks ]
Secondary Outcome Measures :
Proportion of patient with at least 75% reduction in CW lesion counts [ Time Frame: 16 weeks ]
Proportion of patient with at least 50% reduction in lesion size (volume) [ Time Frame: 16 weeks ]
Mean of percent reduction in CW lesion counts from individual patient by visit [ Time Frame: 16 weeks ]
Mean of percent reduction in CW lesion size from individual patient by visit [ Time Frame: 16 weeks ]
CW recurrence rate [ Time Frame: 28 weeks ]
Time to complete clearance [ Time Frame: 16 weeks ]
Percent reduction for pooled lesion counts by visit [ Time Frame: 16 weeks ]
Safety: evaluate the changes occurring from baseline (Randomization visit) to EOT visit. [ Time Frame: 28 weeks ]
including PE, vital sign, lab. test, local skin reaction, and adverse event, etc.
Inclution Criteria
Inclusion Criteria:
Age ≥ 17 years old.
The diagnosis of CW is based on visual inspection by an experienced dermatologist.
Patient is selected ≤ 5 CW lesions; each of the target lesion(s) needs to be ≤ 15 mm in diameter. For patient with only 1 selected lesion, the size of target lesion needs to be measuring 2 to 15 mm in diameter.
Patient agrees to apply the study medication on target CW lesion(s) with an occlusive dressing for at least 20 hours per day.
Patient or the legally acceptable representative of patient under 20 years of age, is willing and able to provide written informed consent.
Patient agrees not to use wart-removing product/modality (prescription or over-the-counter) other than the study product during the course of the study; and is willing to refrain from using cosmetics or other topical products in the treatment area for the duration of the study.
Any non-target CW receiving wart-removing procedures including cryotherapy and surgical therapy should be at least 5 cm apart from the target lesions.
Patient is free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk to the patient.
Patient is judged to be in good health based upon the results of physical examinations (PEs), medical history, and safety laboratory tests.
Patient in good general health condition (performance status ≤ 2 Eastern Cooperative Oncology Group (ECOG)).
Patient agrees to be photographed of the CW target lesion(s) and used of such data as part of the study package.
Female patient of childbearing potential should have a negative urine or serum pregnancy test at Screening day, and is willing to use effective contraception during the study.
Age ≥ 17 years old.
The diagnosis of CW is based on visual inspection by an experienced dermatologist.
Patient is selected ≤ 5 CW lesions; each of the target lesion(s) needs to be ≤ 15 mm in diameter. For patient with only 1 selected lesion, the size of target lesion needs to be measuring 2 to 15 mm in diameter.
Patient agrees to apply the study medication on target CW lesion(s) with an occlusive dressing for at least 20 hours per day.
Patient or the legally acceptable representative of patient under 20 years of age, is willing and able to provide written informed consent.
Patient agrees not to use wart-removing product/modality (prescription or over-the-counter) other than the study product during the course of the study; and is willing to refrain from using cosmetics or other topical products in the treatment area for the duration of the study.
Any non-target CW receiving wart-removing procedures including cryotherapy and surgical therapy should be at least 5 cm apart from the target lesions.
Patient is free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk to the patient.
Patient is judged to be in good health based upon the results of physical examinations (PEs), medical history, and safety laboratory tests.
Patient in good general health condition (performance status ≤ 2 Eastern Cooperative Oncology Group (ECOG)).
Patient agrees to be photographed of the CW target lesion(s) and used of such data as part of the study package.
Female patient of childbearing potential should have a negative urine or serum pregnancy test at Screening day, and is willing to use effective contraception during the study.
Exclusion Criteria
Exclusion Criteria:
The treatment area is located in any of the following areas: the eye area (including eyelids), lips, mouth cavity, nasal cavity,inner ear, soles of the feet, underneath the nails, and the anogenital area.
Patient had participated in a clinical study within 30 days prior to the Randomization visit, or is currently participating in another clinical study.
Patient had used any wart-removing product/modality in the treatment area within 30 days prior to the Randomization visit or received cryotherapy in the treatment area within 60 days prior to the Randomization visit.
Patient who has immune-compromised conditions, have required or will require systemic intake of immunosuppressive or immunomodulatory medication (oral or parental corticosteroids are included) within 30 days prior to the Randomization visit or during the course of the study. Routine use of inhaled or intranasal corticosteroids during the study is allowed.
Patient has clinically significant or unstable medical conditions (psychologically and physically) in any of the following listed situations:
- Clinically significant peripheral vascular disease based on medical history.
- Current uncontrolled infection, current skin infections and/or skin disorder in the treatment area other than CW and/or in the area surrounding the warts that may confound or affect study assessment procedure of the study endpoints.
- Chronic or acute medical condition that, in the opinion of the investigator, may interfere with the study results or place the subject at undue risk (including human immunodeficiency virus, systemic lupus erythematosis, active viral hepatitis, etc.).
Patient is pregnant, plan to become pregnant, or is breastfeeding.
Patient has a history of allergy or sensitivity to Solanum undatum plant extract, SM, or SR-T100 gel excipients including carbomer, propylene glycol, and triethanolamine.
The treatment area is located in any of the following areas: the eye area (including eyelids), lips, mouth cavity, nasal cavity,inner ear, soles of the feet, underneath the nails, and the anogenital area.
Patient had participated in a clinical study within 30 days prior to the Randomization visit, or is currently participating in another clinical study.
Patient had used any wart-removing product/modality in the treatment area within 30 days prior to the Randomization visit or received cryotherapy in the treatment area within 60 days prior to the Randomization visit.
Patient who has immune-compromised conditions, have required or will require systemic intake of immunosuppressive or immunomodulatory medication (oral or parental corticosteroids are included) within 30 days prior to the Randomization visit or during the course of the study. Routine use of inhaled or intranasal corticosteroids during the study is allowed.
Patient has clinically significant or unstable medical conditions (psychologically and physically) in any of the following listed situations:
- Clinically significant peripheral vascular disease based on medical history.
- Current uncontrolled infection, current skin infections and/or skin disorder in the treatment area other than CW and/or in the area surrounding the warts that may confound or affect study assessment procedure of the study endpoints.
- Chronic or acute medical condition that, in the opinion of the investigator, may interfere with the study results or place the subject at undue risk (including human immunodeficiency virus, systemic lupus erythematosis, active viral hepatitis, etc.).
Patient is pregnant, plan to become pregnant, or is breastfeeding.
Patient has a history of allergy or sensitivity to Solanum undatum plant extract, SM, or SR-T100 gel excipients including carbomer, propylene glycol, and triethanolamine.
The Estimated Number of Participants
-
Taiwan
102 participants
-
Global
0 participants
